MedPath

Continuous Regional Arterial Infusion of Low Molecular Weight Heparin in Patients With Severe Acute Pancreatitis

Not Applicable
Conditions
Acute Pancreatitis
Registration Number
NCT01626911
Lead Sponsor
Nanjing University School of Medicine
Brief Summary

Our animal studies found that continuous regional arterial infusion (CRAI in the celiac trunk) of low molecular weight heparin (LMWH) could alleviate inflammation, improve global hemodynamics and restore organ function in a porcine model of severe acute pancreatitis (SAP,unpublished).

In this study, the investigators aim to evaluate the effects of CRAI of LMWH in the treatment of SAP patients. The investigators suppose CRAI could help improve the outcomes of these patients.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Symptoms and signs of severe acute pancreatitis according to Atlanta criteria
  • Within 3 days from the onset of the disease
  • Available for interventional treatment(not sensible to radiocontrast agent)
Exclusion Criteria
  • Pregnant pancreatitis
  • Receiving surgery or aspiration before;need of early surgery
  • Patients with coagulation disorders

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
coagulation related complications14 days after the placement of celiac trunk catheter

bleeding for the most

coagulative parameters

Pancreatic infection28 days
Secondary Outcome Measures
NameTimeMethod
Hospital durationParticipants will be followed until the date of discharge from the hospital,assessed up to 3 months. Patients who die during hospitalization are excluded from this measurement.
MortalityParticipants will be followed until the date of discharge or the date of death from any cause, whichever came first, assessed up to 3 months
pancreatic necrosis28 days
ICU durationParticipants will be followed until the date of discharge from the ICU,assessed up to 6 weeks. Patients who die during hospitalization are excluded from this measurement.

Trial Locations

Locations (1)

Department of SICU, Research Institute of General Surgery Jinling Hospital, Nanjing, Jiangsu, China

🇨🇳

Nanjing, Jiangsu, China

Department of SICU, Research Institute of General Surgery Jinling Hospital, Nanjing, Jiangsu, China
🇨🇳Nanjing, Jiangsu, China
Weiqin Li, Dr
Contact
+86-025-80860066
kkb9832@gmail.com
Lu Ke, Dr
Sub Investigator
Luyao Zhang, Dr
Sub Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.